Transgene S.A. (0OCQ) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

And thank you for standing by. Welcome to the Transgenic 2025 Half-Year Financial Results Conference Call and Webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be the question and answer session. To ask a question during the session, you need to press star, one, one on your cell phone keypad. You will hear an automatic message advising your hand is raised. To withdraw a question, please press star, one, and one again. If you wish to ask a question via the webcast, please use the Q&A box available on the webcast link anytime during live events. Please be advised that this conference has been recorded. I would now like to hand the conference over to our first speaker today, Lucie Larguet, Chief Financial Officer. Please go ahead, Madam. Thank you, Nadia, and good afternoon, everyone. Thank you for joining us on today's call to discuss our progress over the first half of 2025, as well as our half-year results. You can access the press release issue today on the investor page of our website. On today's call is Dr. Alessandro Riva, our chairman and CEO. After Alessandro's discussion, we will take questions already on the telephone call and also on the web platform. Before we begin, I'd like to remind everyone that today's discussion contains forward-looking statements which are subject to a number of risks and uncertainties. And with this, I now hand over the call to Alessandro. Thank you, Lucy, and good afternoon, everyone. I would say that it has been an exciting first half of the year, not only for transgene individualized therapeutic vaccine, but also, and more importantly, for the head and neck cancer community. We presented the full 24 months of this free survival data for all Phase I patients treated in a ...